You are currently viewing a new version of our website. To view the old version click .
Biomedicines
  • Retraction
  • Open Access

28 October 2025

RETRACTED: Sudha et al. Triazole Modified Tetraiodothyroacetic Acid Conjugated to Polyethylene Glycol, a Thyrointegrin αvβ3 Antagonist as a Radio- and Chemo-Sensitizer in Pancreatic Cancer. Biomedicines 2022, 10, 795

,
,
and
1
The Pharmaceutical Research Institute, Albany College of Pharmacy and Health Sciences, Rensselaer, NY 12144, USA
2
Institute of Engineering in Medicine, University of California, San Diego, CA 92093, USA
*
Author to whom correspondence should be addressed.
This article belongs to the Section Cancer Biology and Oncology
The journal retracts the article “Triazole Modified Tetraiodothyroacetic Acid Conjugated to Polyethylene Glycol, a Thyrointegrin αvβ3 Antagonist as a Radio- and Chemo-Sensitizer in Pancreatic Cancer” [1] cited above.
Following publication, concerns were brought to the attention of the Editorial Office regarding the integrity of and images presented in this publication [1].
Adhering to our standard procedure, an investigation was conducted by the Editorial Office and Editorial Board that identified indications of inappropriate editing and similarities among the subfigures presented in Figure 3. While the authors collaborated within this process, the raw material meeting the journal’s requirements for original images could not be provided for Editorial Board evaluation. Consequently, the Editorial Board has lost confidence in the reliability of the findings and has decided to retract this publication, as per MDPI’s retraction policy (https://www.mdpi.com/ethics#_bookmark30).
This retraction was approved by the Editor-in-Chief of the journal Biomedicines. The authors did not provide a comment on this decision.

Reference

  1. Sudha, T.; Godugu, K.; Glinsky, G.V.; Mousa, S.A. RETRACTED: Triazole Modified Tetraiodothyroacetic Acid Conjugated to Polyethylene Glycol, a Thyrointegrin αvβ3 Antagonist as a Radio- and Chemo-Sensitizer in Pancreatic Cancer. Biomedicines 2022, 10, 795. [Google Scholar] [CrossRef] [PubMed]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Article Metrics

Citations

Article Access Statistics

Multiple requests from the same IP address are counted as one view.